Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry

Fernández-Fabrellas, Estrella ; Molina-Molina, María ; Soriano, Joan B. ; Portal, José Antonio Rodríguez ; Ancochea, Julio ; Valenzuela, Claudia ; Xaubet, Antoni ; Aburto Barrenetxea, M. ; Alfageme Michavila, I. ; Bollo de Miguel, E. ; Cano, E. ; Casanova Espinosa, A. ; Castillo Villegas, D. ; Figuerola Mendal, J. A. (Universidad de Zaragoza) ; García Sevila, R. ; Gaudó Navarro, J. I. ; Gómez Carrera, L. ; González, J. M. ; Herrera Lara, S. ; Laporta Hernández, R. ; Marín González, M. ; Nieto Barbero, M. A. ; Portillo, K. ; Romero, A. D. ; Sánchez Simón-Talero, R. ; Sancho Chust, J. N. ; Sellarés Torres, J. ; Soler Sempere, M. J. ; Sauleda Roig, J. ; Tomás López, L. ; Villanueva Montes, M.
Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry
Resumen: BackgroundLittle is known on the characteristics of patients diagnosed with idiopathic pulmonary fibrosis (IPF) in Spain. We aimed to characterize the demographic and clinical profile of IPF patients included in the IPF National Registry of the Spanish Respiratory Society (SEPAR).MethodsThis is a prospective, observational, multicentre and nationwide study that involved 608 IPF patients included in the SEPAR IPF Registry up to June 27th, 2017, and who received any treatment for their disease. IPF patients were predominantly males, ex-smokers, and aged in their 70s, similar to other registries.ResultsUpon inclusion, meanSD predicted forced vital capacity was 77.6%+/- 19.4, diffusing capacity for carbon monoxide was 48.5%+/- 17.7, and the 6-min walk distance was 423.5m +/- 110.4. The diagnosis was mainly established on results from the high-resolution computed tomography in the proper clinical context (55.0% of patients), while 21.2% of patients required invasive procedures (surgical lung biopsy) for definitive diagnosis. Anti-fibrotic treatment was prescribed in 69.4% of cases, 51.5% pirfenidone and 17.9% nintedanib, overall with a good safety profile.Conclusions The SEPAR IPF Registry should help to further characterize current characteristics and future trends of IPF patients in Spain and compare/pool them with other registries and cohorts.
Idioma: Inglés
DOI: 10.1186/s12931-019-1084-0
Año: 2019
Publicado en: Respiratory research 20 (2019), 127 [10 pp]
ISSN: 1465-9921

Factor impacto JCR: 3.924 (2019)
Categ. JCR: RESPIRATORY SYSTEM rank: 18 / 64 = 0.281 (2019) - Q2 - T1
Factor impacto SCIMAGO: 1.436 - Pulmonary and Respiratory Medicine (Q1)

Tipo y forma: Article (Published version)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Exportado de SIDERAL (2020-07-16-08:43:32)

Este artículo se encuentra en las siguientes colecciones:

 Record created 2019-08-23, last modified 2020-07-16

Versión publicada:
Rate this document:

Rate this document:
(Not yet reviewed)